| Literature DB >> 34599661 |
Rickard Zeijlon1,2, Victor Hantelius3, Susanna M Wallerstedt4,5, Lina Holmqvist3,6,7.
Abstract
PURPOSE: This meta-epidemiological study aimed to systematically review case reports regarding sports nutrition supplements and adverse events (AEs), specifically addressing the issue of causality assessments.Entities:
Keywords: Adverse event; Causality assessment; Clinical reasoning; Dietary supplement
Mesh:
Year: 2021 PMID: 34599661 PMCID: PMC8724217 DOI: 10.1007/s00228-021-03223-9
Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN: 0031-6970 Impact factor: 2.953
Fig. 1Flowchart of the study selection
Characteristics of reported cases (n = 97)
| Prevalence in study cohort | Information provided | |
|---|---|---|
| n (%) if not stated otherwise | n (%) of total | |
| Age, median (range) | 30 (14–60) | 96 (99%) |
| Male sex | 82 (85%) | 95 (98%) |
| Previously healthy* | 58 (85%) | 68 (70%) |
| Somatic disease† | 8 (12%) | 68 (70%) |
| Psychiatric disorder§ | 4 (6%) | 68 (70%) |
| > 1 supplement identified as responsible for AE | 20 (21%) | 94 (97%) |
| Use of concomitant supplements** | 20 (28%) | 72 (74%) |
| Used ≥ 1 regular prescription drug/s | 14 (27%) | 52 (54%) |
| Smoked tobacco | 8 (26%) | 31 (32%) |
| Consumed alcohol | 19 (49%) | 39 (40%) |
| Used illicit drugs | 3 (8%) | 40 (41%) |
| Symptom duration < 30 days | 37 (44%) | 84 (87%) |
| Fatal AE | 6 (6%) | 97 (100%) |
| Adulteration | 2 (2%) | N/A |
*No chronic or regularly medicated somatic or psychiatric disease; †Any chronic somatic disease or somatic disease requiring regular prescription drug/s; §Any chronic psychiatric disorder or psychiatric disorder requiring regular prescription drug/s/; **Concomitant use of any other supplement than the one identified as responsible of adverse event
AE adverse event, N/A not applicable without analysis of sports nutrition supplement
Suspected substances for the most frequently reported adverse events
For each AE, the number of individuals where the specific substance was the only suspected substance is provided. The number of additional times when the specific substance was reported as one of the suspected substances is provided within parentheses. For specific substances, numbers > 0 are bolded
| Hepatotoxicity | Acne vulgaris | Rhabdo-myolysis | Acute renal injury | AMI | Cardiac arrest | Acute psychosis | Cerebral hemorrhage | Other AE* | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Protein | 0 ( | 0 (+ 0) | 0 ( | 0 ( | 0 (+ 0) | 0 ( | 0 (+ 0) | 1 | 11 | |
| DMAA | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 ( | 0 (+ 0) | 1 | 6 | ||
| Caffeine | 0 (+ 0) | 0 (+ 0) | 0 ( | 0 ( | 0 ( | 0 ( | 0 | 4 | ||
| Creatine | 0 ( | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 ( | 0 (+ 0) | 2 | 3 | |
| Methasteron | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 | 3 | |
| Testosterone | 0 (+ 0) | 0 (+ 0) | 0 ( | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 1 | 3 | |
| Anabolic steroid | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 1 | 3 | |
| Synephrine | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 | 2 | |
| Methylstenbolone | 0 ( | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 | 0 |
| Nandrolone | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 ( | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 | 0 |
| Citrus aurantium | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 ( | 0 (+ 0) | 0 ( | 0 (+ 0) | 0 | 0 |
| Unknown substance | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 0 (+ 0) | 3 | 8 | |||
| Other substance† | 6 | 0 | 3 | 6 | 4 | 2 | 5 | 2 | 26 | 54 |
| 14 | 10 | 9 | 7 | 6 | 6 | 5 | 5 | 35 | 97 |
*Other AE than those specified with either one suspected AE per individual or combinations of suspected AEs per individual; †Other substance than those specified either as one suspected substance per individual or as a combination of substances per individual
AE adverse event, AMI acute myocardial infarction, DMAA 1,3-dimethylamylamine
Fatal cases
| Case No | Year | Age | Sex | Co-morbidity | Substance | Supplement name | Adverse event | Cause of death |
|---|---|---|---|---|---|---|---|---|
| 1 [ | 2010 | 42 | Male | Diabetes | Creatine (in combination with metformin) | Not specified | Acute renal failure with lactate acidosis | Cardiac arrest |
| 2 [ | 2012 | 32 | Male | Sickle cell trait | DMAA, caffeine | Not specified | Cardiac arrest | Cardiac arrest |
| 3 [ | 2012 | 22 | Female | Previously healthy | DMAA, caffeine | Not specified | Cardiac arrest | Cardiac arrest |
| 4 [ | 2013 | 35 | Male | Previously healthy | Arsenic, anabolic steroid (arsenic contamination found in supplement analysis)* | Performance enhancer (unspecified) | Arsenic poisoning | Multi-organ failure |
| 5 [ | 2013 | 39 | Male | NR | Caffeine | Caffeine Anhydrous Powder | Cardiac arrest | Cardiac arrest |
| 6 [ | 2015 | 30 | Female | Previously healthy | DMAA | Jack3D | Cardiac arrest | Cardiac arrest |
*Substances originating from > 1 supplement product
DMAA 1,3-dimethylamylamine, NR not reported
Causality assessments factors, according to the use of clinical reasoning
| Factors of relevance for causality assessment | Clinical reasoning | ||||
|---|---|---|---|---|---|
| All (n=97) | Yes (n=61) | No (n=36) | P-value | ||
| Information reported regarding… | |||||
| Patient characteristics | Previous health condition | 68 (67%) | 44 (72%) | 24 (67%) | 0.57 |
| Use of medications | 52 (54%) | 37 (61%) | 15 (42%) | 0.070 | |
| Smoking status | 31 (32%) | 18 (30%) | 13 (36%) | 0.50 | |
| Alcohol use | 39 (40%) | 30 (49%) | 9 (25%) | 0.019 | |
| Illicit drug use | 40 (41%) | 28 (46%) | 12 (33%) | 0.22 | |
| Concomitant supplement use* | 72 (74%) | 49 (80%) | 23 (64%) | 0.074 | |
| AE characteristics | Positive time relationship | 95 (98%) | 59 (97%) | 36 (100%) | 0.27 |
| Response to withdrawal | 78 (80%) | 49 (80%) | 29 (81%) | 0.98 | |
| Previous cases | 81 (84%) | 55 (90%) | 26 (72%) | 0.021 | |
| Re-challenge† | 2 (2%) | 1 (2%) | 1 (3%) | 0.70 | |
| Supplement characteristics | Theoretic rationale | 84 (87%) | 56 (92%) | 28 (78%) | 0.050 |
| Body fluid analysis** | 12 (12%) | 11 (18%) | 1 (3%) | 0.027 | |
| Supplement analysis†† | 4 (4%) | 3 (5%) | 1 (3%) | 0.61 |
*Concomitant use of any other supplement than the one identified as responsible of adverse event; †Culprit supplement or substance re-administered for the purpose of reproducing observed index adverse event; **In vivo analysis of substances from sports nutrition supplement in body fluid; ††In vitro analysis of the sports nutrition supplement
AE adverse event
Causality assessments factors, according to the use systematic causality assessment methods
| Factors of relevance for causality assessment | Systematic causality assessment | ||||
|---|---|---|---|---|---|
| All* (n=61) | Yes (n=8) | No (n=53) | P-value | ||
| Information reported regarding… | |||||
| Patient characteristics | Use of medications | 68 (70%) | 8 (100%) | 36 (68%) | 0.059 |
| Smoking status | 37 (61%) | 8 (100%) | 29 (55%) | 0.015 | |
| Alcohol use | 18 (30%) | 4 (50%) | 14 (26%) | 0.17 | |
| Illicit drug use | 30 (49%) | 7 (88%) | 23 (43%) | 0.020 | |
| Concomitant supplement use† | 28 (46%) | 7 (88%) | 21 (40%) | 0.011 | |
| Use of medications | 49 (80%) | 7 (88%) | 42 (79%) | 0.58 | |
| AE characteristics | Positive time relationship | 59 (97%) | 8 (100%) | 51 (96%) | 0.58 |
| Response to withdrawal | 49 (80%) | 8 (100%) | 41 (77%) | 0.13 | |
| Previous cases | 55 (90%) | 7 (88%) | 48 (91%) | 0.79 | |
| Re-challenge** | 1 (2%) | 0 (0%) | 1 (2%) | 0.70 | |
| Sports nutrition supplement characteristics | Theoretic rationale | 56 (92%) | 7 (88%) | 49 (93%) | 0.63 |
| Body fluid analysis†† | 11 (18%) | 0 (0%) | 11 (21%) | 0.16 | |
| Supplement analysis§ | 3 (5%) | 1 (13%) | 2 (4%) | 0.29 |
*All cases with clinical reasoning; †Concomitant use of any other supplement than the one identified as responsible of adverse event; **Culprit supplement or substance re-administered for the purpose of reproducing observed index adverse event; ††In vivo analysis of substances from sports nutrition supplement in body fluid; §In vitro analysis of the sports nutrition supplement
AE adverse event